Imagin Competitors

Pink Sheets . USA . 
Stock . Imagin Medical
IMEXF Stock  USD 0.0001  0.00  0.00%   
Imagin Medical competes with Vivos Therapeutics, Cerus, Boston Scientific, Novacyt SA, and Aethlon Medical; as well as few others. The company classifies itself under Healthcare sector and is part of Medical Devices industry. Analyzing Imagin Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Imagin Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Imagin Medical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Imagin Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Imagin Medical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000117.33
Details
Intrinsic
Valuation
LowRealHigh
0.000.00009617.33
Details

Imagin Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Imagin Medical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Imagin and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Imagin Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RWLK
+ 0.85
VVOS
CTSO
+ 0.79
NVYTF
BSX
+ 0.59
VVOS
RWLK
+ 0.42
BSX
AEMD
+ 0.27
VVOS
VYCO
+ 0.22
CERS
  
High negative correlations   
NVYTF
- 0.8
BSX
CTSO
- 0.68
BSX
NVYTF
- 0.58
VVOS
NHNKY
- 0.43
BSX
CTSO
- 0.41
VVOS
VYCO
- 0.38
RWLK

Risk-Adjusted Indicators

There is a big difference between Imagin Pink Sheet performing well and Imagin Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Imagin Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VVOS  4.01  0.78  0.16 (432.15) 3.96 
(4.61)
 9.43 
(6.90)
 19.92 
CERS  3.03 (0.19) 0.00 (0.04) 0.00 
 0.00 
 7.19 
(7.33)
 21.37 
BSX  0.71  0.08  0.07  0.61  0.81 
(0.78)
 1.67 
(1.50)
 6.63 
NVYTF  1.70 (0.54) 0.00  0.54  0.00 
 0.00 
 0.00 
(8.57)
 31.38 
AEMD  5.27  1.30  0.14 (0.33) 5.85 
(9.92)
 7.89 
(6.98)
 113.23 
RWLK  2.18  0.19  0.07  0.93  1.97 
(3.33)
 5.26 
(3.33)
 21.49 
CTSO  4.29 (0.78) 0.00 (0.44) 0.00 
 0.00 
 6.98 
(10.00)
 36.66 
OSSUY  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
NHNKY  3.83  0.16  0.03  0.28  4.85 
(3.58)
 6.93 
(7.94)
 24.32 
VYCO  4.95  0.53  0.02 (21.60) 8.42 
(16.88)
 15.79 
(11.63)
 86.27 
All Fundamental Data

Imagin Medical Competitive Analysis

The better you understand Imagin Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Imagin Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Imagin Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IMEXF VVOS CERS BSX NVYTF AEMD RWLK CTSO OSSUY NHNKY
 0.00 
 0.0001 
Imagin
 6.87 
 4.98 
Vivos
 6.51 
 1.58 
Cerus
 0.33 
 88.95 
Boston
 3.13 
 0.62 
Novacyt
 5.17 
 0.55 
Aethlon
 1.33 
 0.74 
Rewalk
 8.70 
 0.84 
Cytosorbents
 0.00 
 4.05 
Ssur
 1.22 
 14.16 
Nihon
Market Volatility
(90 Days Market Risk)
Out of control
Very risky
Very risky
Very steady
Abnormally volatile
Moderately volatile
Very steady
Dangerous
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Good
Very Weak
OK
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very High
Quite High
High
Very Small
Low
High
Dangerous
Very High
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Not Available
Buy
Not Available
Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Cautious Hold
Strong Hold
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Hold
Strong Sell
Current Ratio
0.04
3.15
2.08
1.45
4.66
9.66
22.05
3.95
0.93
3.73
Net Asset
1.35 M
10.73 M
197.75 M
35.14 B
183.7 M
8.25 M
74.24 M
53.26 M
1.33 B
210.2 B
Profit Margin
N/A
-0.86
-0.11
0.11
-0.0957
N/A
-2.38
-0.49
0.0592
0.0763
EBITDA
(2.44 M)
(16.68 M)
(26.54 M)
3.45 B
(1.71 M)
(11.85 M)
(19.04 M)
(28.81 M)
116.74 M
37.76 B
Current Valuation
7.9 M
19.41 M
315.76 M
139.85 B
(50.49 M)
1.96 M
28.94 M
71.19 M
2.3 B
1.58 B
Price To Book
9.05
3.14
5.49
6.33
0.4
1.33
1.15
3.85
2.53
1.64
Operating Margin
N/A
-0.48
-0.0209
0.17
0.0673
N/A
-1.24
-0.46
0.0934
0.0945
Retained Earnings
N/A
(93.05 M)
(1.04 B)
819 M
N/A
(154.57 M)
(213.75 M)
(282.51 M)
N/A
83.97 B
Current Asset
N/A
N/A
130.41 M
1.21 B
N/A
817 K
23.78 M
9.05 M
N/A
100.09 B
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.35
Beta
1.5
7.68
1.2
0.8
-2.16
1.76
2.31
0.56
0.59
-0.12
Number Of Employees
15
114
625
48 K
210
14
56
186
3.89 K
5.64 K
Shares Outstanding
10.83 M
4.84 M
185.72 M
1.47 B
70.63 M
13.96 M
60.02 M
54.95 M
420.29 M
168.25 M
Cash Flow From Operations
(2.63 M)
(11.95 M)
(43.17 M)
2.5 B
15.69 M
(10.13 M)
(20.1 M)
(21.66 M)
60.77 M
25.7 B
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0184
0.0191
Total Debt
8.95 M
2 M
96 M
9.49 B
1.67 M
940.32 K
897 K
18.31 M
277.71 M
325 M
Return On Equity
N/A
-2.85
-0.38
0.0892
-0.0198
-1.05
-0.34
-1.18
0.0685
0.0988
Z Score
-3.3
N/A
N/A
N/A
29.4
N/A
38.5
N/A
3.6
3.6
Return On Asset
-2.37
-0.57
-0.0373
0.049
0.0145
-0.5
-0.17
-0.28
0.0326
0.0598
Book Value Per Share
-1.23
0.22
0.29
14.05
1.88
2.19
0.86
0.24
1.51
958.31
Number Of Shares Shorted
N/A
114.84 K
6.62 M
12.25 M
N/A
203.4 K
1.36 M
1.37 M
N/A
N/A
Current Liabilities
N/A
N/A
21.86 M
923 M
N/A
1.08 M
4.34 M
5 M
N/A
33.24 B
Total Asset
1.35 M
10.73 M
197.75 M
35.14 B
183.7 M
8.25 M
74.24 M
53.26 M
1.33 B
210.2 B
Debt To Equity
2.1
0.11
1.15
0.51
0.012
0.047
0.01
0.28
0.74
0.002
Short Ratio
N/A
0.66
4.1
2.0
N/A
0.98
2.82
9.57
N/A
N/A
Target Price
N/A
6.3
3.9
99.14
N/A
3.85
3.0
5.0
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
40.0
Shares Owned By Institutions
N/A
13.72
79.21
92.44
1.6
3.09
20.71
33.28
N/A
0.071
Market Capitalization
1.84 M
24.08 M
293.43 M
132.44 B
83.34 M
7.73 M
63.03 M
46.07 M
1.87 B
2.12 B
Price To Earning
-3.47
N/A
-4.7
107.05
0.51
-1.14
-0.77
-16.3
145.2
15.72
Price To Earnings To Growth
N/A
N/A
N/A
1.61
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
1.72
1.67
8.32
1.04
2.37
6.89
1.22
2.62
0.0099
Net Income
(2.49 M)
(13.58 M)
(37.49 M)
1.59 B
(9.73 M)
(12.21 M)
(21.81 M)
(28.51 M)
42.51 M
23.43 B
Earnings Per Share
-0.9
-4.99
-0.11
1.21
-0.17
-2.79
-0.36
-0.36
0.11
0.89
Shares Owned By Insiders
12.46
1.51
3.25
0.18
3.49
0.5
1.96
3.9
N/A
N/A
Revenue
N/A
13.8 M
156.37 M
14.24 B
95.78 M
N/A
9.15 M
36.35 M
718.65 M
205.13 B
Working Capital
N/A
(4.83 M)
76.92 M
1.58 B
N/A
4.4 M
67.73 M
11.16 M
N/A
66.85 B
Cash And Equivalents
145.67 K
17.83 M
107.05 M
928 M
99.65 M
14.92 M
78.83 M
30.16 M
66.8 M
54.54 B
Cash Per Share
0.01
0.77
0.6
0.24
1.41
0.65
1.25
0.69
0.16
324.25
Gross Profit
N/A
12.6 M
87.09 M
8.68 B
64.87 M
574.25 K
1.91 M
20.73 M
439.75 M
109.09 B
Day Typical Price
1.0E-4
4.9
1.58
88.62
0.62
0.57
0.75
0.86
4.05
14.15
Accumulation Distribution
N/A
0.0996
51127.31
0.027
N/A
1.1 M
0.0519
36812.34
N/A
618.31
Market Facilitation Index
N/A
0.51
N/A
2.42
N/A
N/A
0.04
N/A
N/A
8.0E-4
Daily Balance Of Power
0.0
0.6275
(1.57)
0.1198
(9,223,372,036,855)
(0.23)
(0.25)
(0.73)
0.0
0.062
Period Momentum Indicator
N/A
0.32
(0.11)
0.29
(0.02)
(0.03)
(0.01)
(0.08)
N/A
0.17
Rate Of Daily Change
1.0
1.07
0.93
1.0
0.97
0.95
0.99
0.91
1.0
1.01
Day Median Price
1.0E-4
4.87
1.59
88.46
0.62
0.59
0.75
0.87
4.05
14.14
Price Action Indicator
N/A
0.28
(0.06)
0.64
(0.01)
(0.05)
(0.01)
(0.07)
N/A
0.11
Coefficient Of Variation
(1,456)
642.59
(3,794)
1044.57
(823.27)
987.2
1646.11
(853.89)
N/A
2752.59
Mean Deviation
6.61
4.01
3.03
0.7091
1.7
5.27
2.18
4.29
N/A
3.83
Jensen Alpha
(1.15)
0.7779
(0.19)
0.0838
(0.54)
1.3
0.1882
(0.78)
N/A
0.1557
Total Risk Alpha
(1.72)
0.6298
(0.24)
0.0574
(0.70)
0.86
0.0953
(0.93)
N/A
0.0251
Sortino Ratio
N/A
0.1611
N/A
0.0675
N/A
0.1428
0.0674
N/A
N/A
0.0281
Downside Variance
N/A
21.94
N/A
0.8973
N/A
69.43
6.35
N/A
N/A
27.25
Standard Deviation
17.44
5.06
4.21
1.01
4.57
12.07
3.34
6.26
N/A
4.95
Kurtosis
17.06
(0.21)
1.5
3.35
17.95
27.43
9.65
4.54
N/A
(0.09)
Potential Upside
20.0
9.43
7.19
1.67
N/A
7.89
5.26
6.98
N/A
6.93
Treynor Ratio
0.5163
(432.15)
(0.04)
0.6069
0.5379
(0.33)
0.9348
(0.44)
N/A
0.2809
Maximum Drawdown
149.33
19.92
21.37
6.63
31.38
113.23
21.49
36.66
N/A
24.32
Variance
304.26
25.63
17.7
1.03
20.85
145.77
11.16
39.24
N/A
24.46
Market Risk Adjusted Performance
0.5263
(432.14)
(0.03)
0.6169
0.5479
(0.32)
0.9448
(0.43)
N/A
0.2909
Risk Adjusted Performance
(0.04)
0.1317
(0.01)
0.078
(0.09)
0.0896
0.0558
(0.08)
N/A
0.0372
Skewness
(2.29)
0.1399
0.4555
0.3755
(0.09)
4.07
2.44
0.8408
N/A
0.1409
Semi Deviation
N/A
3.96
N/A
0.8053
N/A
5.85
1.97
N/A
N/A
4.85
Information Ratio
(0.07)
0.1491
(0.03)
0.063
(0.13)
0.0985
0.0508
(0.12)
N/A
0.0296
Value At Risk
(33.33)
(6.90)
(7.33)
(1.50)
(8.57)
(6.98)
(3.33)
(10.00)
N/A
(7.94)
Expected Short fall
N/A
(4.61)
N/A
(0.78)
N/A
(9.92)
(3.33)
N/A
N/A
(3.58)
Downside Deviation
N/A
4.68
N/A
0.9473
N/A
8.33
2.52
N/A
N/A
5.22
Semi Variance
N/A
15.67
N/A
0.6485
N/A
34.23
3.87
N/A
N/A
23.55

Imagin Medical Competition Performance Charts

Five steps to successful analysis of Imagin Medical Competition

Imagin Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Imagin Medical in relation to its competition. Imagin Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Imagin Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Imagin Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Imagin Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Imagin Medical position

In addition to having Imagin Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Imagin Pink Sheet

Imagin Medical financial ratios help investors to determine whether Imagin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Imagin with respect to the benefits of owning Imagin Medical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY